SACHI BIOWORKS, INC.

Sachi Bioworks is a biotechnology company developing Nanoligomer-based nucleic acid therapeutics for precision drug discovery. Their robotic platform rapidly synthesizes and validates gene-targeting molecules — capable of producing thousands of drug candidates per day — to enable personalized medicines targeting any gene in any organism. The company has four preclinical drug candidates (Parkinson's, IBD, neuroimmune disease, radiation countermeasures) and is funded by NASA SBIR grants for space medicine applications.